NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's HyBryte(TM) Development and Rare Disease Focus
TL;DR
Soligenix's HyBryte offers investors potential advantage in rare disease market as it nears final study before worldwide regulatory submissions.
HyBryte uses synthetic hypericin in photodynamic therapy with visible light, currently in late-stage Phase 3 trials for cutaneous T-cell lymphoma treatment.
This therapy addresses unmet medical needs for over 30 million Americans with rare diseases, improving quality of life through innovative treatment options.
Soligenix's technology platform also includes heat-stabilized vaccines for threats like ricin and Ebola, showcasing diverse biopharmaceutical innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
The editorial, titled 'Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,' examines the growing burden of rare diseases affecting over 30 million Americans and the urgent need for new therapies, specifically spotlighting Soligenix's HyBryte(TM) development.
HyBryte(TM) (synthetic hypericin) is a novel photodynamic therapy being developed by Soligenix for the treatment of cutaneous T-cell lymphoma (CTCL), utilizing safe visible light.
HyBryte(TM) is in late-stage development, currently in its final confirmatory study before worldwide marketing submissions, following successful completion of a second Phase 3 study.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Soligenix operates through two business segments: Specialized BioTherapeutics (developing treatments like HyBryte for rare diseases) and Public Health Solutions (developing vaccines for threats like ricin, filoviruses, and COVID-19).
Beyond HyBryte for CTCL, Soligenix is expanding synthetic hypericin into psoriasis, developing dusquetide (SGX942) for inflammatory diseases including oral mucositis, and SGX945 for Behcet's Disease.
This segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Soligenix incorporates its proprietary heat stabilization platform technology, known as ThermoVax(R), in the development of its vaccine programs.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
The editorial places Soligenix's efforts at the intersection of advancing treatment options for rare diseases and emerging national health policy initiatives, highlighting the importance of both therapeutic development and supportive policy frameworks.
Curated from InvestorBrandNetwork (IBN)
